Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population. RESEARCH DESIGN AND METHODS: In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Every center also recruited at a 1:1 ratio untreated control subjects matched for age and sex. All patients had pneumonia and exhibited oxygen saturation <95% when breathing ambient air or when receiving oxygen support. The primary end points were discharge from the hospital/death and improvement of clinical outcomes, defined as an increase in at least two points on a seven-category modified ordinal scale. Data were collected retrospectively from patients receiving sitagliptin from 1 March through 30 April 2020. RESULTS: Of the 338 consecutive patients with type 2 diabetes and COVID-19 admitted in Northern Italy hospitals included in this study, 169 were on sitagliptin, while 169 were on standard of care. Treatment with sitagliptin at the time of hospitalization was associated with reduced mortality (18% vs. 37% of deceased patients; hazard ratio 0.44 [95% CI 0.29–0.66]; P = 0.0001), with an improvement in clinical outcomes (60% vs. 38% of improved patients; P = 0.0001) and with a greater number of hospital discharges (120 vs. 89 of discharged patients; P = 0.0008) compared with patients receiving standard of care, respectively. CONCLUSIONS: In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment. The effects of sitagliptin in patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
COVID-19 and Italy: what next?
Remuzzi, A., & Remuzzi, G. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30627-9 · Cited by 3,119 · cited 1×
“inhibitor with higher selectivity for CD26, may be beneficial in treating COVID-19, particularly in patientswith type2diabetes who appear to be at high risk of mortality and of cardiorenal (25–31) or cerebrovascular complications (1,4).”
BackgroundDeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Qi, F., Qian, S., Zhang, S., & Zhang, Z. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.044 · Cited by 905
Clinical characteristics and outcomes of patients with severe COVID-19 with diabetes
Yan, Y., Yang, Y., Wang, F., Ren, H., Zhang, S., Shi, X., Yu, X., & Dong, K. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001343 · Cited by 572 · cited 1×
“Type2diabetes increasesthemortality risk in patients with COVID-19 (5,23), particularly in those with more severe disease (24).”
BackgroundNiewczas, M. A., Pavkov, M. E., Skupien, J., Smiles, A., Md Dom, Z. I., Wilson, J. M., Park, J., Nair, V., Schlafly, A., Saulnier, P.-J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0415-5 · Cited by 432 · cited 1×
“Other oral antidiabetic agents 50 (31) 61 (34) 0.”
BackgroundSelf-citationCoronavirus infections and type 2 diabetes-shared pathways with therapeutic implications
Drucker, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa011 · Cited by 399
Cited by
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection
Montefusco, L., Ben Nasr, M., D’Addio, F., Loretelli, C., Rossi, A., Pastore, I., Daniele, G., Abdelsalam, A., Maestroni, A., Dell’Acqua, M., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00407-6 · Cited by 423
Self-citationDiabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning
Drucker, D. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.016 · Cited by 272
Maiorino, M. I., Longo, M., Scappaticcio, L., Bellastella, G., Chiodini, P., Esposito, K., & Giugliano, D. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01401-8 · Cited by 72
Anti-inflammatory effects of diet and caloric restriction in metabolic syndrome
Montefusco, L., D’Addio, F., Loretelli, C., Ben Nasr, M., Garziano, M., Rossi, A., Pastore, I., Plebani, L., Lunati, M. E., Bolla, A. M., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01547-y · Cited by 65
Self-citationFerretti, F., Cannatelli, R., Benucci, M., Carmagnola, S., Clementi, E., Danelli, P., Dilillo, D., Fiorina, P., Galli, M., Gallieni, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656362 · Cited by 39
“The presence of poor glucometabolic control is associated with a further increase of mortality as compared to those patients within target (103).”
BackgroundResultSelf-citation
Metadata
- Authors
- Solerte, S. B., D’Addio, F., Trevisan, R., Lovati, E., Rossi, A., Pastore, I., Dell’Acqua, M., Ippolito, E., Scaranna, C., Bellante, R., Galliani, S., Dodesini, A. R., Lepore, G., Geni, F., Fiorina, R. M., Catena, E., Corsico, A., Colombo, R., Mirani, M., De Riva, C., Oleandri, S. E., Abdi, R., Bonventre, J. V., Rusconi, S., Folli, F., Di Sabatino, A., Zuccotti, G., Galli, M., & Fiorina, P.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-09-29
- Volume
- 43
- Issue
- 12
- Pages
- 2999-3006
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3089727605
- Cited by
- 244
- References
- 8
- FWCI
- 33.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.